Clinical Impact of the Line Probe Assay and Xpert® MTB/RIF Assay in the Presumptive Diagnosis of Drug-Resistant Tuberculosis in Brazil: A Pragmatic Clinical Trial.
Afrânio Lineu KritskiMaria Martha OliveiraIsabela Neves de AlmeidaDaniela RamalhoMônica Kramer de Noronha AndradeMônica Carvalho de Mesquita Werner WermelingerPryscila Fernandes Campino MirandaMargareth Maria Pretti DalcolmoJose Ueleres BragaTania BrígidoEliene MesquitaClaudia Fontoura DiasAglae GambirasioJoao Baptista Souza FilhoAnne DetjenPatrick Peter John PhillipsIvor LangleyPaula FujiwaraStephen Bertel SquirePublished in: Revista da Sociedade Brasileira de Medicina Tropical (2022)
In the Xpert arm, there was a significant reduction in days to the start of appropriate anti-TB treatment and a trend towards greater culture conversion in the sixth month.
Keyphrases
- drug resistant
- mycobacterium tuberculosis
- pulmonary tuberculosis
- multidrug resistant
- clinical trial
- acinetobacter baumannii
- high throughput
- study protocol
- quantum dots
- living cells
- emergency department
- randomized controlled trial
- pseudomonas aeruginosa
- hiv aids
- cystic fibrosis
- phase iii
- replacement therapy
- human immunodeficiency virus
- smoking cessation
- single cell